Lifecore Biomedical, Inc. De (LFCR) Debt to Equity (2011 - 2025)

Lifecore Biomedical's Debt to Equity history runs 15 years deep, the most recent figure standing at $4.34 for Q2 2025.

• In Q2 2025, Debt to Equity fell 51.64% year-over-year to $4.34; the TTM figure through May 2025 stood at $4.34 (down 51.64% YoY), while the FY2025 annual figure was $4.34, down 51.64% from the prior year.
• Debt to Equity was $4.34 for Q2 2025 at Lifecore Biomedical, up from $3.74 in the prior quarter.
• In the past five years, Debt to Equity ranged from a high of $12.42 in Q4 2023 to a low of -$20.06 in Q2 2023.
• Historically, Debt to Equity has averaged $0.96 across 5 years, with a median of $1.01 in 2021.
• The sharpest annual moves came in 2023 and 2024: Debt to Equity tumbled 1894.05% in 2023, then surged 1101.82% in 2024.
• A 5-year view of Debt to Equity shows it stood at $1.07 in 2021, then surged by 30.08% to $1.39 in 2022, then soared by 793.06% to $12.42 in 2023, then slumped by 95.17% to $0.6 in 2024, then soared by 623.4% to $4.34 in 2025.
• The last three Debt to Equity figures came in at $4.34 (Q2 2025), $3.74 (Q1 2025), and $0.6 (Q4 2024), per Business Quant data.